{
    "clinical_study": {
        "@rank": "87192", 
        "arm_group": [
            {
                "arm_group_label": "Alvimopan", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to determine whether an oral perioperative medication (alvimopan--a\n      selective mu antagonist) improves bowel recovery over placebo after surgery for ovarian\n      cancer."
        }, 
        "brief_title": "Accelerating Gastrointestinal Recovery", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ovarian Cancer", 
            "Fallopian Tube Cancer", 
            "Primary Peritoneal Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Ovarian Neoplasms", 
                "Peritoneal Neoplasms", 
                "Fallopian Tube Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Females at least 18 years of age\n\n          -  Have an American Society of Anesthesiologists (ASA) Score of I to III\n\n          -  Are consented for primary, interval, or secondary cytoreduction for ovarian, tubal,\n             or peritoneal cancer\n\n          -  Are scheduled to have their nasogastric tube removed before the first postoperative\n             dose of study medication\n\n          -  Are able to understand the study procedures, have agreed to participate in the study\n             program, and have voluntarily provided informed consent\n\n        Exclusion criteria:\n\n          -  Females younger than 18 years of age\n\n          -  Known non-gynecologic malignancy presenting with similar signs/symptoms as ovarian,\n             tubal, or peritoneal cancer.\n\n          -  Have taken more than 7 consecutive days of therapeutic doses of opioids immediately\n             prior to surgery\n\n          -  Use illicit drugs or abuse alcohol\n\n          -  Have had a prior total colectomy, gastrectomy, gastric bypass, or have a functional\n             colostomy or ileostomy\n\n          -  Have an ongoing history of short bowel syndrome, chronic constipation (\u22643 spontaneous\n             bowel movements per week) or chronic diarrhea\n\n          -  Have received radiation therapy to the abdomen or pelvis within 3 months of scheduled\n             surgery\n\n          -  Have chemotherapy or radiation induced bowel dysfunction\n\n          -  Are pregnant (identified by a positive urine or serum pregnancy test) or lactating,\n             or are not postmenopausal (no menses for at least 1 year) and are of childbearing\n             potential and not using an accepted method of birth control (ie, surgical\n             sterilization, intrauterine contraceptive device, oral contraceptive, diaphragm, or\n             condom in combination with contraceptive cream, jelly, or foam, or abstinence)\n\n          -  Have participated in another investigational drug or medical device study within 30\n             days of surgery or will be enrolled in another investigational drug or medical device\n             study or any study in which active patient participation is required outside normal\n             hospital data collection during the course of this study\n\n          -  Have clinically significant laboratory abnormalities at screening that would result\n             in the cancellation of surgery\n\n          -  Have a diagnosis of severe hepatic insufficiency or end stage renal disease.\n\n          -  Have a history of previous surgeries, illness, or behavior that in the opinion of the\n             investigator might confound the study results or pose additional risk in\n             administering the study procedures\n\n          -  Are unable to understand the study procedures and are not able to voluntarily\n             provided informed consent"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "134", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01704651", 
            "org_study_id": "12-004082"
        }, 
        "intervention": [
            {
                "arm_group_label": "Alvimopan", 
                "description": "Perioperative administration of oral alvimopan", 
                "intervention_name": "Alvimopan", 
                "intervention_type": "Drug", 
                "other_name": "Entereg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Perioperative administration of placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ovary", 
            "Ovarian", 
            "Fallopian", 
            "Peritoneal", 
            "Cancer", 
            "Gynecological", 
            "Female"
        ], 
        "lastchanged_date": "February 19, 2014", 
        "location": {
            "contact": {
                "email": "lemens.maureen@mayo.edu", 
                "last_name": "Maureen A Lemens, BSN, RN", 
                "phone": "507-293-1487"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial", 
        "overall_contact": {
            "email": "lemens.maureen@mayo.edu", 
            "last_name": "Maureen A Lemens, BSN, RN", 
            "phone": "507-293-1487"
        }, 
        "overall_contact_backup": {
            "last_name": "Marla Kay S Sommerfield", 
            "phone": "507-266-3053"
        }, 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Jamie Bakkum-Gamez, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Postoperative length of hospital stay", 
            "safety_issue": "No", 
            "time_frame": "Patients will be followed for the duration of their hospital stay, an expected average of 5 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01704651"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Jamie N. Bakkum-Gamez", 
            "investigator_title": "Consultant and Assistant Professor of Obstetrics-Gynecology,", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Postoperative ileus incidence", 
            "safety_issue": "No", 
            "time_frame": "Patients will be followed for 30 days postop"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "collaborator": {
                "agency": "Cubist Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Jamie N. Bakkum-Gamez", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}